-
1.Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors 有权
Title translation: 融合的吡啶,嘧啶和三嗪化合物作为细胞周期抑制剂公开(公告)号:US08980903B2
公开(公告)日:2015-03-17
申请号:US14453842
申请日:2014-08-07
Applicant: Amgen Inc.
Inventor: Richard V. Connors , Kang Dai , John Eksterowicz , Pingchen Fan , Benjamin Fisher , Jiasheng Fu , Kexue Li , Zhihong Li , Lawrence R. McGee , Rajiv Sharma , Xiaodong Wang , Dustin L. McMinn , Jeffrey T. Mihalic , Jeffrey Deignan
IPC: C07D498/04 , C07D491/147 , C07D471/14 , C07D471/04 , C07D487/14 , C07D491/107 , C07D498/10
CPC classification number: C07D471/14 , A61K31/519 , A61K31/5377 , A61K31/5386 , C07D403/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/14 , C07D491/107 , C07D491/147 , C07D498/04 , C07D498/10 , C07D513/14
Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives.
Abstract translation: 提供了可用于治疗CDK4介导的疾病如癌症的化合物,药物组合物和方法。 本发明化合物是吡啶,吡嗪酰亚胺和三嗪衍生物。